An ultrahigh-dose of methylcobalamin slows functional decline by 43% in patients with early-stage amyotrophic lateral sclerosis (ALS), new research shows. The 50-mg dose was administered twice-weekly ...
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a type of motor neuron disease. The condition damages the motor neurons, which control muscle movement in a person’s body. It is often ...
Degradation of motor neurons, conceptual computer illustration. Motor neuron diseases are a group of neurodegenerative disorders including amyotrophic lateral sclerosis, progressive bulbar palsy and ...
A study of 137 patients found edaravone use lead to less functional loss than placebo, contrasting with results from a previous Phase 3 study which found no efficacy of the treatment over placebo.
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig disease, is a progressive, always-fatal neuromuscular disease characterized by motor neuron degeneration in the brain and spinal cord. As upper and ...
Our top 10 ALS news stories of 2025 feature actor Eric Dane’s advocacy and major research milestones in the field.
The MarketWatch News Department was not involved in the creation of this content. This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to ...
Boston, MA and Providence, RI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for ...
(Reuters) -Drug developer Denali Therapeutics said on Friday its and partner Sanofi's experimental drug for a fatal neurodegenerative disease failed to slow decline of motor function in a mid-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback